Moderator of 2 Sessions
Presenter of 1 Presentation
COMBINATION THERAPY WITH TOPOTECAN, PACLITAXEL, AND BEVACIZUMAB IMPROVES PROGRESSION-FREE SURVIVAL IN PATIENTS WITH RECURRENT HIGH-GRADE NEUROENDOCRINE CARCINOMA OF THE CERVIX: A NECTUR STUDY
Abstract
Objectives
The objective of this study was to evaluate the efficacy of the three-drug regimen topotecan, paclitaxel, and bevacizumab (TPB) in women with recurrent high-grade neuroendocrine cervical cancer (HGNECC).
Methods
This retrospective cohort study used data from the Neuroendocrine Cervical Tumor Registry (NeCTuR). The study compared women with recurrent HGNECC who received TPB as first- or second-line therapy for recurrence and women with recurrent HGNECC who received chemotherapy but not TPB. Progression-free survival from the start of treatment for recurrence to the next recurrence or death, overall survival from first recurrence, and response rates were evaluated.
Results
The study included 57 patients who received TPB as first- or second-line treatment for recurrence and 48 patients who received chemotherapy but not TPB for recurrence. Median progression-free survival was 8.2 months in the TPBgroup compared to 3.1 months in the non-TPBgroup, with a hazard ratio for progression of 0.23 (95% CI 0.14-0.40; P < 0.0001). In the TPB group, 16% had stable disease, 38% had a partial response, and 16% had a complete response. Significantly more patients in the TPB group than in the non-TPB group remained on treatment at 6 months (67% vs. 25%, P = 0.0002) and 1 year (24% vs. 6%, P = 0.03). Median overall survival was 16.9 months in the TPBgroup compared to 14.0 months in the non-TPB group, with a hazard ratio for death of 0.89 (95% CI 0.55-1.45).
Conclusions
TPB is an active regimen in women with recurrent HGNECC and improves progression-free survival while decreasing the hazard ratio for progression.